Abstract Mineralocorticoid receptor antagonists (MRAs) improve survival and reduce morbidity in patients with heart failure, reduced ejection fraction (HFREF), and mild-to-severe symptoms, and in ...

European Heart Journal, Zannad, Faiez, Gattis Stough, Wendy, Rossignol, Patrick, Bauersachs, Johann, McMurray, John J.V., Swedberg, Karl, Struthers, Allan D., Voors, Adriaan A., Ruilope, Luis M., ...